Alseres Pharmaceuticals (Alseres Pharmaceuticals) Risk Assessment

View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Alseres Pharmaceuticals is: No Data: Cannot be evaluated.

Competitive Comparison of Alseres Pharmaceuticals's Risk Assessment

For the Biotechnology subindustry, Alseres Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alseres Pharmaceuticals's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alseres Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Alseres Pharmaceuticals's Risk Assessment falls into.

Alseres Pharmaceuticals (OTCPK:ALSE) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Alseres Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466

Website

http://www.alseres.com

Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.

Executives

Mark Jerome Pykett	officer: President and COO	223A MAIN ST, BOXFORD MA 021921
Robert Langer	director	98 MONTVALE RD, NEWTON MA 02459
Peter G Savas	director, officer: Chief Executive Officer	110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston	director	C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr	officer: Exec VP of Fin & Admin & CFO	C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon	officer: Chief Financial Officer	1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck	director	P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines

From GuruFocus

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 08-14-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus • 05-15-2009

Alseres Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-16-2009